Nocion Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$93M
- Investors
-
16
Nocion Therapeutics General Information
Description
Developer of a small molecule charged sodium channel designed to treat the conditions arising from neurogenic inflammation. The company creates notions that target activated sensory neurons and enter activated nociceptors via large-pore channels on these neurons, enabling patients to gain relief through the treatment of serious conditions, including cough, itch, pain, and inflammation.
Contact Information
Website
www.nociontx.comCorporate Office
- 15 Main Street
- Number 247
- Watertown, MA 02472
- United States
Corporate Office
- 15 Main Street
- Number 247
- Watertown, MA 02472
- United States
Nocion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 07-Jan-2026 | $93M | Completed | Clinical Trials - Phase 2 | ||
| 6. Early Stage VC (Series A2) | 30-Aug-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC (Series A1) | 05-Jan-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Accelerator/Incubator | 18-Apr-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 16-Jul-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Nocion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 28,458,714 | $0.000100 | 4% | $0.71 | $0.71 | 1x | $0.71 | 4.74% |
| Series A | 51,527,350 | $0.000100 | 4% | $0.55 | $0.55 | 1x | $0.55 | 8.59% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nocion Therapeutics Comparisons
Industry
Financing
Details
Nocion Therapeutics Competitors (86)
One of Nocion Therapeutics’s 86 competitors is Neurona Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| ImmunOs Therapeutics | Venture Capital-Backed | Schlieren, Switzerland | ||||
| OncoTartis | Venture Capital-Backed | Orchard Park, NY | ||||
| NeRRe Therapeutics | Venture Capital-Backed | Stevenage, United Kingdom | ||||
| Plexium | Venture Capital-Backed | San Diego, CA |
Nocion Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nocion Therapeutics Patents
Nocion Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260060989-A1 | Charged ion channel blockers and methods for use | Pending | 06-Mar-2024 | ||
| WO-2025188837-A1 | Charged ion channel blockers and methods for use | Pending | 06-Mar-2024 | ||
| WO-2025188837-A8 | Charged ion channel blockers and methods for use | Pending | 06-Mar-2024 | ||
| AU-2023265825-A1 | Compositions and methods for treatment of inflammatory bowel disease | Pending | 03-May-2022 | ||
| EP-4519247-A1 | Compositions and methods for treatment of inflammatory bowel disease | Inactive | 03-May-2022 | A61K31/4425 |
Nocion Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nocion Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arkin Capital | Asset Manager | Minority | ||
| Lumira Ventures | Venture Capital | Minority | ||
| Monograph Capital | Venture Capital | Minority | ||
| Morningside Group | Venture Capital | Minority | ||
| Morningside Private Investors | PE/Buyout | Minority |
Nocion Therapeutics FAQs
-
When was Nocion Therapeutics founded?
Nocion Therapeutics was founded in 2017.
-
Where is Nocion Therapeutics headquartered?
Nocion Therapeutics is headquartered in Watertown, MA.
-
What is the size of Nocion Therapeutics?
Nocion Therapeutics has 17 total employees.
-
What industry is Nocion Therapeutics in?
Nocion Therapeutics’s primary industry is Drug Discovery.
-
Is Nocion Therapeutics a private or public company?
Nocion Therapeutics is a Private company.
-
What is Nocion Therapeutics’s current revenue?
The current revenue for Nocion Therapeutics is .
-
How much funding has Nocion Therapeutics raised over time?
Nocion Therapeutics has raised $153M.
-
Who are Nocion Therapeutics’s investors?
Arkin Capital, Lumira Ventures, Monograph Capital, Morningside Group, and Morningside Private Investors are 5 of 16 investors who have invested in Nocion Therapeutics.
-
Who are Nocion Therapeutics’s competitors?
Neurona Therapeutics, ImmunOs Therapeutics, OncoTartis, NeRRe Therapeutics, and Plexium are some of the 86 competitors of Nocion Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
